On Monday, Shares of Hilton Worldwide Holdings Inc. (NYSE:HLT), lost -0.63% to $28.42.
Hilton Worldwide Holdings, declared the signing of a administration agreement with Pinnacle Nexus Sdn. Bhd. (a member of Cornerstone Partners) to open DoubleTree Resort by Hilton Penang. Located in the northern beach area of Penang near the UNESCO World Heritage Site of George Town, DoubleTree by Hilton Penang Resort will add to the existing pipeline of five hotels in Malaysia where Hilton Worldwide presently operates six hotels under the Hilton and DoubleTree by Hilton brands.
“We are very happy to be working with a well-respected partner such as Pinnacle Nexus to introduce the DoubleTree by Hilton brand to Penang. The signing of this agreement underscores our commitment to developing Hilton Worldwide’s portfolio of brands in Malaysia. DoubleTree Resort by Hilton Penang will be a tremendous addition to the brand’s rapidly-expanding global portfolio across six continents and at the same time, bolster the country’s tourism profile to attract more travelers to Malaysia,” said Andrew Clough, senior vice president of development, Middle East & Asia Pacific, Hilton Worldwide.
Penang is one of the top three economic centers amongst the states of Malaysia, as the country’s manufacturing hub for major international high-tech electronics companies. Well known for being a tourist destination, Penang has tremendous potential as it continues to develop its MICE infrastructure in addition to medical tourism offerings.
Hilton Worldwide Holdings Inc., a hospitality company, owns, leases, manages, develops, and franchises hotels, resorts, and timeshare properties worldwide. The company operates hotels under 12 brand names, counting Hilton Hotels & Resorts, Waldorf Astoria Hotels & Resorts, Conrad Hotels & Resorts, Canopy by Hilton, Curio - A Collection by Hilton, DoubleTree by Hilton, Embassy Suites Hotels, Hilton Garden Inn, Hampton Hotels, Homewood Suites by Hilton, Home2 Suites by Hilton, and Hilton Grand Vacations.
Shares of Express Scripts Holding Company (NASDAQ:ESRX), inclined 0.42% to $87.78, during its last trading session.
Express Scripts Holding Company, declared that its Board of Directors has elected Tim Wentworth to the Board.
Mr. Wentworth is presently the President of Express Scripts, a role he has held since 2014. He has administration responsibility for all aspects of the company’s core business, and reports directly to George Paz, Express Scripts’ Chairman and CEO.
“We are happy to welcome Tim to the Express Scripts Board of Directors, and appreciate the combination of planned leadership, unique insights and industry expertise he brings to our Board,” said Mr. Paz. “Tim and I have worked closely together to develop and execute a long-term growth strategy that leverages our core strengths, establishes new innovative solutions and makes medicine affordable and accessible for payers and patients.”
Express Scripts Holding Company operates as a pharmacy benefit administration (PBM) company in the United States and Canada. The company operates through two segments, PBM and Other Business Operations.
Finally, Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), ended its last trade with 4.20% gain, and closed at $3.72.
Idera Pharmaceuticals, declared that the company has reached a planned clinical research alliance with The University of Texas MD Anderson Cancer Center to advance clinical development of intratumoral TLR9 agonist in combination with checkpoint inhibitors. IMO-2125 is a TLR9 agonist which has been evaluated subcutaneously in over 80 human subjects, was well tolerated, and was shown to induce immune responses.
The company intends to initiate the first trial of the research alliance, a Phase 1/2 study to assess the safety and efficacy of Intratumoral IMO-2125 in combination with ipilimumab (a CTLA4 antibody) in patients with metastatic melanoma. In this trial, escalating doses of IMO-2125 will be administered intratumorally into a lesion, with a standard dosing regimen of ipilimumab. The primary objectives of the trial will be to determine the maximum tolerated dose (MTD) and characterize the dose-limiting toxicities (DLTs) of IMO-2125 when administered intratumorally in combination with ipilimumab, in addition to to determine the efficacy of the combination utilizing the immune-related response criteria (irRC). The company has already filed and received FDA feedback to a Pre-Investigational New Drug Application (PIND) for IMO-2125 and intends to submit an Investigational New Drug application (IND) and initiate the clinical study in the second half of this year. The trial will enroll about 45 patients. The company anticipates data to be accessible in 2016. The study will be led by Adi Diab, MD, Assistant Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, MD Anderson. Additional trials as part of the broader, clinical research alliance are presently in the planning stages.
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for oncology and rare diseases in the United States. It uses two proprietary drug discovery technology platforms to design and develop drug candidates, counting toll-like receptor targeting technology and gene silencing oligonucleotide (GSO) technology.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
